AASLD 2016 Comp Review

AASLD 2016 Comp Review 

AASLD_2016_CompReview_button_v2.png


About the Program

Program Overview

The Advances in Chronic Hepatitis C: Management and Treatment program is a comprehensive, independent review of the 67th American Association for the Study of Liver Diseases Annual Meeting (AASLD 2016). This program consists of four components: (1) CME Internet Symposium: AASLD 2016 Expert Review: a 1.5 hour Internet symposium that features an overview and discussion of key presentations and posters, selected by the expert faculty discussants; (2) Comprehensive Expert Review and Discussion of Key Presentations: an on-line, in-depth review of 8 of the key poster/presentations reviewed in the Internet symposium (3) Rapid-Fire Independent Review of AASLD 2016: a podcast that provides a brief, audio summary of the most essential data presented at the conference; and (4) From Conference To Clinic: Reviewing And Applying Data From AASLD 2016: case-based dinner meetings during which the key data are reviewed, discussed and applied to patient care.

The Comprehensive Expert Review and Discussion of Key Presentations part of the program will feature HCV experts reviewing and discussing the most important studies on chronic hepatitis C therapy presented at AASLD 2016. This review and discussion will provide a comprehensive overview of each of the posters and presentations selected. In addition, the faculty will provide unique insights into how knowledgeable experts review and analyze data from AASLD and an in-depth understanding of the scientific quality and clinical relevance of the posters and presentations reviewed.

All online components of the program will be accessible at www.viraled.com.

This program is produced by the Postgraduate Institute for Medicine and ViralEd, Inc. It is not a session created by or presented at AASLD 2016 and it is not sanctioned by the organizers of AASLD 2016.

Back to Top  

Target Audience

This activity has been designed to meet the educational needs of physicians, physician assistants, advanced practice nurses and other health care professionals involved in the care of patients with HCV infection.

Back to Top

Learning Objectives

After completing this activity, the participant should be better able to:

  • Use in a clinical setting important findings from key studies on CHC diagnosis and treatment presented at AASLD 2016

  • Employ current treatment protocols for CHC in clinical practice, including the studies and data presented at AASLD 2016, to improve patient care

  • Engage patients and colleagues in a discussion on studies and data presented at AASLD 2016 relevant to new therapies for CHC to determine the appropriate treatment for patients with CHC

Release Date: November 30, 2016

Expiration Date: November 30, 2017

Estimated time to complete each Poster/Presentation: 15-30 minutes 

Media: Internet

Back to Top 

Faculty

Paul J. Pockros, MD
Head, Division of Gastroenterology/Hepatology
Director, SC Liver Research Consortium
The Scripps Clinic
La Jolla, California

Jürgen Rockstroh, MD 
Professor of Medicine
Department of Medicine I
University Hospital
Bonn, Germany

Paul Kwo, MD
Professor of Medicine
Medical Director, Liver Transplantation
Division of Gastroenterology and Hepatology
Indiana University School of Medicine
Indianapolis, Indiana

Douglas T. Dieterich, MD
Professor of Medicine and Director of CME
Department of Medicine
Director of Outpatient Hepatology
Division of Liver Diseases
Mount Sinai School of Medicine
New York, New York

Back to Top  

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Postgraduate Institute for Medicine and ViralEd, Inc. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Back to Top

Credit Designation

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. There will be 8 posters and presentations available for a total of 2.00 possible credit hours.

Back to Top

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to provideing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commerical interest.

Doug Dieterich, MD

  • Consulting Fees: Gilead, BMS, AbbVie, Janssen
  • Fees for Non-CME/CE Services: Gilead, BMS, AbbVie, Janssen
  • Contracted Research: Gilead, BMS, AbbVie, Janssen

Paul Kwo, MD

  • Consulting Fees: Abbott, Abbvie, Quest, CVS, BMS, Gilead, Janssen, Merck, Alnylam
  • Contracted Research: Abbvie, BMS, Gilead, Janssen, Merck,Conatus
  • Other (DSMB): Inovio

Paul Pockros, MD

  • Consulting Fees: Gilead, BMS, Merck, Abbvie
  • Fees for Non-CME/CE Services: Gilead, Merck, Abbvie, BMS
  • Contracted Research: Gilead, BMS, Merck, Genfit, Intercept, Medicinova, RMS, Janssen (To Scripps Health)

Juergen Rockstroh, MD

  • Consulting Fees: Abbott, Abbvie, Bionor, BMS, Cipla, Gilead, Janssen, Merck, ViiV
  • Fees for Non-CME/CE Services: Abbvie, BMS, Gilead, Janssen, Merck
  • Contracted Research: Gilead
The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of these CME activities:

The PIM planners and managers, Trace Hutchison, PharmD,  Samantha Mattiucci, PharmD, CHCP, Judi Smelker-Mitchek, MBA, MSN, RN and Jan Shultz, MSN, RN, CHCP have nothing to disclose.

Disclosure of Unlableled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The Postgraduate Institute for Medicine, ViralEd, Inc., Merck and Co. and Gilead Sciences Medical Affairs. do not recommend the use of any agent outside of the labeled indications. 

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the Postgraduate Institute for Medicine, ViralEd, Inc., Merck and Co. and Gilead Sciences Medical Affairs. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Poster/Presentation Listing

 AASLD_16_Abst78_v2.jpg Real-world Outcomes With New HCV Antivirals in HIV/HCV-coinfected Subjects: Madrid Coinfection Registry (Madrid-CoRE) Findings
 AASLD_16_ABSTLB17_v2.jpg Hepatitis B Reactivation Associated with Direct Acting Antiviral Therapy for Hepatitis C: A Review of Spontaneous Post-Marketing Cases
 AASLD_16_ABST253_v2.jpg ENDURANCE-1: Efficacy and Safety of 8- versus 12-week Treatment with ABT-493/ABT-530 in patients with Chronic HCV Genotype 1 Infection
 AASLD_16_ABSTLB17.jpg EXPEDITION-IV: Safety and Efficacy of GLE/PIB in Adults with renal impairment and Chronic Hepatitis C Virus Genotype 1 - 6 Infection
 AASLD_16_Abst110.jpg Safety and Efficacy of the Fixed-Dose Combination Regimen of MK-3682/Grazoprevir/MK-8408 With or Without Ribavirin in Non-cirrhotic or Cirrhotic Patients with CHC GT1, 2 or 3 Infection (Part B of C-CREST-1 & 2)
 AASLD_16_Abst193 Safety and Efficacy of the Fixed-Dose Combination Regimen of MK-3682/Grazoprevir/MK-8408 in Cirrhotic or Non-cirrhotic Patients with Chronic HCV GT1 Infection who Previously Failed a Direct-acting Antiviral Regimen (C-SURGE)
 AASLD_16_AbstLB-12 A Randomized Phase 3 Trial of Sofosbuvir/Velpatasvir/ Voxilaprevir for 8 Weeks Compared to Sofosbuvir/Velpatasvir for 12 Weeks in DAA-Naïve Genotype 1-6  HCV-Infected Patients: The POLARIS-2 Study
 AASLD_16_Abst194 Sofosbuvir/Velpatasvir/Voxilaprevir for 12 Weeks as a Salvage Regimen in NS5A Inhibitor-Experienced Patients with Genotype 1-6 Infection: The Phase 3 POLARIS-1 Study

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.    

PIM_small

This program is produced by the Postgraduate Institute for Medicine and ViralEd, Inc. It is not a session created by or presented at AASLD 2016 and it is not sanctioned by the organizers of AASLD 2016.

This activity is supported by an independent educational grant from Merck & Co. 

Prepare to print

Share this page:

Get link code to this page                     


Back to Top